secwatch.observer — SEC 8-K summary
======================================

Issuer:     HCW Biologics Inc. (HCWB)
CIK:        0001828673
Form:       8-K
Filed at:   2025-11-14T23:59:59+00:00
Accession:  0001193125-25-283230
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

HCW Biologics Q3 net loss $4.6M; going concern doubt; first patient dosing expected Q4 2025
--------------------------------------------------------------------------------

- Revenue fell to $15,606 from $426,423 YoY; net loss $4.6M vs $3.9M.
- Substantial doubt about going concern for 12 months from Sep 30, 2025.
- Nasdaq Panel granted continued listing subject to compliance with Equity Rule by Dec 31, 2025.
- Issued 475,000 shares for $2.2M gross proceeds via Standby Equity Purchase Agreement.
- Phase 1 trial of HCW9302 in autoimmune disease to dose first patient Q4 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1828673/000119312525283230/0001193125-25-283230-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1828673/000119312525283230/hcwb-20251114.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-283230

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer